Literature DB >> 17092567

Role of IFN-alpha/beta signaling in the prevention of genital herpes virus type 2 infection.

Alexandra Svensson1, Lars Bellner, Mattias Magnusson, Kristina Eriksson.   

Abstract

This study has shown that IFN-alpha/beta signaling is crucial for combating primary herpes simplex virus type 2 (HSV-2) infection and for responding to immunotherapy using ligands to TLR3, 7 and 9, but not for vaccine-induced immunity. Both genital viral replication and the disease progression were enhanced in HSV-2-infected mice lacking the IFN-alpha/beta receptor (IFN-alpha/betaR-/-). IFN-alpha/betaR-/- mice were, however, able to mount a normal HSV-2-specific Th1 response and acquired sterilizing immunity following vaccination. Anti-viral treatments using agonists to TLR3, 7 and 9 by administration of synthetic dsRNA, imiquimod and oligonucleotides containing unmethylated CpG motifs, respectively, were strongly dependent on IFN-alpha/beta receptor signaling for their efficacy. Even though all treatments had a weak impact on local vaginal viral replication in infected IFN-alpha/betaR-/- animals, they did not affect disease progression or mortality in these animals as opposed to wild type controls where all three treatments reduced viral replication as well as disease severity and mortality. Lack of IFN-alpha/betaR signaling also blocked production of IFN-gamma and TNF-alpha in response to TLR9 activation. These studies have shown that IFN-alpha/beta receptor signaling is important for multiple events in the anti-viral defense.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17092567     DOI: 10.1016/j.jri.2006.09.002

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  22 in total

1.  Activation of type I interferon-dependent genes characterizes the "core response" induced by CpG DNA.

Authors:  Folkert Steinhagen; Corinna Meyer; Debra Tross; Mayda Gursel; Takahiro Maeda; Sven Klaschik; Dennis M Klinman
Journal:  J Leukoc Biol       Date:  2012-07-02       Impact factor: 4.962

Review 2.  Toll gates to periodontal host modulation and vaccine therapy.

Authors:  George Hajishengallis
Journal:  Periodontol 2000       Date:  2009       Impact factor: 7.589

3.  Rapid clearance of herpes simplex virus type 2 by CD8+ T cells requires high level expression of effector T cell functions.

Authors:  Michelle H Nelson; Melanie D Bird; Chin-Fun Chu; Alison J Johnson; Brian M Friedrich; Windy R Allman; Gregg N Milligan
Journal:  J Reprod Immunol       Date:  2011-03-27       Impact factor: 4.054

Review 4.  Animal models of herpes simplex virus immunity and pathogenesis.

Authors:  Christina M Kollias; Richard B Huneke; Brian Wigdahl; Stephen R Jennings
Journal:  J Neurovirol       Date:  2014-11-12       Impact factor: 2.643

5.  Inhibition of γ-secretase cleavage in the notch signaling pathway blocks HSV-2-induced type I and type II interferon production.

Authors:  Alexandra Svensson; Emely Jäkärä; Andrey Shestakov; Kristina Eriksson
Journal:  Viral Immunol       Date:  2010-12       Impact factor: 2.257

6.  Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection.

Authors:  Christopher D Conrady; William P Halford; Daniel J J Carr
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

7.  Novel roles of cytoplasmic ICP0: proteasome-independent functions of the RING finger are required to block interferon-stimulated gene production but not to promote viral replication.

Authors:  Kathryne E Taylor; Marianne V Chew; Ali A Ashkar; Karen L Mossman
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

8.  Chemokines and Chemokine Receptors Critical to Host Resistance following Genital Herpes Simplex Virus Type 2 (HSV-2) Infection.

Authors:  M Thapa; D J J Carr
Journal:  Open Immunol J       Date:  2008

9.  The role of stress mediators in modulation of cytokine production by ethanol.

Authors:  Mitzi Glover; Bing Cheng; Ruping Fan; Stephen Pruett
Journal:  Toxicol Appl Pharmacol       Date:  2009-06-03       Impact factor: 4.219

10.  FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection.

Authors:  William A Rose; Chris L McGowin; Richard B Pyles
Journal:  Virol J       Date:  2009-11-10       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.